Even the dumbest GBM practitioner will be able to figure out that a placebo arm with 64 crossover patients and 28-29 permanent placebos that registered an mOS of over 24 months from randomization, owes its unusually long survival stats to the DCVax-L treatments that the 64 crossovers received after progression.
If anyone has a better explanation, please let me know.